Skip to main content
TipRanks
Go Ultimate75% OFF

Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP) AI Stock Analysis

11 Followers
GB:BXP

Beximco Pharmaceuticals Limited Sponsored GDR RegS

(LSE:BXP)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP) vs. iShares MSCI United Kingdom ETF (EWC)

-10%0%10%20%30%40%50%60%70%GB:BXP+54.52%EWC+16.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$256.51M
Dividend Yield
7.52%
Average Volume (3M)
22.80K
Price to Earnings (P/E)
4.5
Beta (1Y)
-0.18
Revenue Growth
3.86%
EPS Growth
19.11%
Country
UK
Employees
6,000
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Beximco Pharmaceuticals Limited Sponsored GDR RegS Business Overview & Revenue Model

Company Description

Established in 1976 and headquartered in Dhaka, Bangladesh, Beximco Pharmaceuticals Limited is a prominent company engaged in the production and distribution of generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). The fir...

Beximco Pharmaceuticals Limited Sponsored GDR RegS Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:BXP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:HIKGB:HIK74OutperformGBP 3.47B12.3815.05%3.76%2.48%3.36%
GB:VLGGB:VLG65NeutralGBP 82.26M15.827.82%―――
GB:HLNGB:HLN63NeutralGBP 30.09B18.929.89%1.34%1.21%8.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:STXGB:STX43NeutralGBP 32.76M-4.0964.57%―36.19%60.75%
GB:AGYGB:AGY38UnderperformGBP 88.66M-1.591684.19%―8.77%-7.14%

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:BXPGB:AGYGB:HIKGB:STXGB:VLGGB:HLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:BXP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS57.5020.2954.52%
GB:AGYAllergy Therapeutics1.40-7.40-84.09%
GB:HIKHikma Pharmaceuticals1685.00190.7012.76%
GB:STXShield Therapeutics3.05-3.70-54.81%
GB:VLGVenture Life69.0010.0016.95%
GB:HLNHaleon PLC343.20-19.06-5.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.